638192-10-6

Basic information

• Product Name: Benzenamine, 4-(difluoromethoxy)-N-methyl- (9CI)
• Synonyms: Benzenamine, 4-(difluoromethoxy)-N-methyl- (9CI)
• CAS NO: 638192-10-6
• Molecular Formula: C₈H₉F₂NO
• Molecular Weight: 173.1599664
• Product Categories: METHOXY
• Mol File: 638192-10-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 230.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.201±0.06 g/cm3(Predicted)
• PKA: 4.32±0.19(Predicted)
• CAS DataBase Reference: Benzenamine, 4-(difluoromethoxy)-N-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 4-(difluoromethoxy)-N-methyl- (9CI)(638192-10-6)
• EPA Substance Registry System: Benzenamine, 4-(difluoromethoxy)-N-methyl- (9CI)(638192-10-6)

Safety Data

• Hazardous Substances Data: 638192-10-6(Hazardous Substances Data)

Upstream product

• 638192-11-7 ethyl(4-difluoromethoxyphenyl)carbamate 
• 22236-10-8 4-difluoromethoxyaniline 

Relevant articles and documents

Highly Efficient Binuclear Copper-catalyzed Oxidation of N,N-Dimethylanilines with O2

A binuclear copper-salicylate complex, [Cu(Sal)2(NCMe)]2 (Sal=salicylate), was found to be an active catalyst for the oxidation of N,N-dimethylanilines by O2, affording the corresponding N-methyl-N-phenylformamides as major products. The reactions were carried out with a O2 balloon and the S/C (substrate/catalyst ratio) of the model reaction could be up to 1×105, providing a practical and highly efficient catalytic protocol for accessing N-methyl-N-phenylformamides.

ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR

This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula (I): where m is zero or one, n is zero to two, Y is oxygen or -N (R9)-, R1, R2, R3, R4, R5, R9, and Ring A are defined in the specification. Coumarin and quinolone compounds where R1 and R2 together form a fused benzo ring are preferred. The invention also provides compounds of formula (VI) where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.